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manchester.ac.ukAbstractGlucocorticoids (Gc) are potent anti-inflammatory agents with wide clinical application. We
have previously shown that increased serum concentration significantly attenuates
regulation of a simple Gc-responsive reporter. We now find that glucocorticoid receptor (GR)
regulation of some endogenous transactivated but not transrepressed genes is impaired,
suggesting template specificity. Serum did not directly affect GR expression, activity or
trafficking, implicating GR crosstalk with other signalling pathways. Indeed, a JNK inhibitor
completely abolished the serum effect. We identified the Gc modulating serum component
as cholesterol. Cholesterol loading mimicked the serum effect, which was readily reversed by
JNK inhibition. Chelation of serum cholesterol with methyl-b-cyclodextrin or inhibition of
cellular cholesterol synthesis with simvastatin potentiated the Gc response. To explore the
effect in vivowe used ApoEK/Kmice, a model of hypercholesterolaemia. Consistent with our
in vitro studies, we find no impact of elevated cholesterol on the expression of GR, or on the
hypothalamic–pituitary–adrenal axis, measured by dexamethasone suppression test. Instead
we find selective Gc resistance on some hepatic target genes in ApoEK/Kmice. Therefore, we
have discovered an unexpected role for cholesterol as a selective modulator of Gc action in
vivo. Taken together these findings reveal a new environmental constraint on Gc action with
relevance to both inflammation and cancer.Key Words
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.0 UJournal of Endocrinology
(2014) 223, 155–166IntroductionGlucocorticoids (Gc) are potent anti-inflammatory
agents and are widely prescribed for the treatment of a
range of inflammatory and immune diseases including
rheumatoid arthritis and asthma (McMaster & Ray 2007,
Barnes & Adcock 2009, De et al. 2011). In humans cortisol
is the principal circulating Gc, but additional modulatory
molecules are present including cortisone and the5a-reduced cortisol metabolites (McMaster et al. 2008,
Nixon et al. 2012).
Natural and synthetic Gc molecules modulate the
activity of the near ubiquitously expressed glucocorticoid
receptor (GR). The GR is amember of the nuclear hormone
receptor superfamily and acts as a ligand-inducible
transcription factor by interacting with chromatin tosed under a Creative Commons
nported License.
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223 :2 156regulate gene transcription (Ito et al. 2006, Schacke et al.
2007, Sommer & Ray 2008). Selection of GR binding sites
across the genome is dependent on cell-type specific
chromatin structure and activity of comodulator proteins
which regulate the accessibility of GR to target DNA
(Herrera et al. 1989, Biddie et al. 2011, John et al. 2011).
Patients’ responses to Gc treatment may vary, which is
amajor factor that limits the therapeutic utility ofGc.Many
human disorders are affected by Gc signalling; therefore,
there is great interest in defining mechanisms underlying
how local tissue Gc sensitivity is being regulated (Yang
et al. 2012). Amongst the best-characterised alterations
in local Gc sensitivity is the acquired resistance that occurs
at foci of inflammation, which is attributed to multiple
pathways including cytokine action and activation of
transcription factors including nuclear factor kappa B
(NFkB) and activator protein 1 (AP1) (Yang et al. 2012).
While developing a sensitive Gc bioassay, we ident-
ified a striking and unexplained effect of serum which
reduced the ability of GR to transactivate a simple reporter
gene (Perogamvros et al. 2011, 2012). Serum contains a
complex mixture of nutritional and signalling com-
ponents, as well as classical hormones. The powerful effect
of serum components on transcriptional responses have
been known for a number of years, primarily through the
activation of serum response factor (SRF) acting at AP1
elements (Treisman 1986, Shaw et al. 1989). More recently,
a blood-borne signal with powerful activity to reset
cellular circadian oscillators was discovered. The circulat-
ing factor in this case was thought to be a polypeptide, as
yet unidentified, but one capable of acting through serum-
response factor (Gerber et al. 2013).
Herein, we define the role of serum components on
regulating Gc sensitivity. We identify cholesterol as a
critical Gc regulatory serum component, and also that
activation of JNKs and AP1 is essential for mediating the
cholesterol effect. We further show that modulating
cellular cholesterol metabolism using statins increases
cellular sensitivity to Gc action. Given that membrane
cholesterol release in response to cell necrosis is found
both in cancers and at sites of inflammation, this provides
a new mechanism to explain how a local environmental
signal can selectively modulate the Gc response.Materials and methods
Dexamethasone (Dex), water soluble cholesterol and
methyl-b-cyclodextrin were purchased from Sigma. The
following antibodies were used: anti-GR (mouse clone 41,
BD Biosciences, San Jose, CA, USA); anti-(s211)phospho-http://joe.endocrinology-journals.org
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Printed in Great BritainGR, anti-JNK and anti-phospho JNK, from Cell Signalling
Technology (Beverly, MA, USA); anti-caveolin-1 from
Santa Cruz; anti-a-tubulin from Sigma; anti-b-actin from
Abcam (Cambridge, UK); and HRP-conjugated anti-mouse
and anti-rabbit from GE Healthcare (Little Chalfont, UK).
Fluorophore-conjugated (Alexa Fluor 546 and 488) anti-
mouse and anti-rabbit antibodies were Invitrogen.
Human WT GRa expression vector and pMMTV-Luc
have been described before (Ray et al. 1996). TAT3-Luc
(Iniguez-Lluhi et al. 1997)was a kind gift fromKYamamoto
(University of California San Francisco, CA, USA). The
pSG5–steroid receptor coactivator 1 (SRC1) expression
vector (Chen et al. 1999) was the kind gift of M Stallcup
(University of Southern California, CA, USA). interleukin 6
(IL6)-Luc reporters were obtained from the BCCM plasmid
collection (Zwijnaarde, Belgium). Expression vectors of
MKK7activated JNKandERK (Tsuruta et al. 2004)were kind
gifts fromA Sharrocks (University ofManchester). pcDNA5
(Invitrogen) was used as an empty control. CMV-Renilla
(Promega) was used to correct for transfection efficiency.Animals
ApoEK/K mice have been described previously (Plump
et al. 1992). Transgenic and WT (C57BL/6) mice were
routinely housed in 12 h light:12 h darkness (L:D) cycles
with ad libitum access to food and water in a pathogen-
free animal facility at the University of Manchester. All
experiments were carried out in strict accordance with
the Animals (Scientific Procedures) act 1986.
Serum samples were collected from age matched
(12–18 weeks) female WT (C57BL/6) and ApoEK/K mice
at morning (0700 h) and evening (1900 h) from the
sequential tail vein bleeds. The following day (1500 h),
animals were weighed and injected with either Dex
(1 mg/kg i.p.) or vehicle control. Four hours later (to
coincide with peak corticosterone levels), mice were killed
(pentobarbital i.p.) and trunk blood was collected for
the assessment of serum lipid and corticosterone levels.
The livers were snap frozen for protein and RNA analysis.Cell culture
Human epithelial carcinoma (HeLa) cells were obtained
from the European Collection of Cell Cultures (Salisbury,
UK) and maintained in DMEM supplemented with
GlutaMAX I and 10% fetal bovine serum (FBS, Invitrogen),
10% charcoal stripped FBS (CSS, Gibco), or lipoprotein
deficient FBS (LDS, Sigma) in a humidified atmosphere
of 5% CO2 at 37 8C.Published by Bioscientifica Ltd
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1!106 cells were transfected with 2 mg of firefly luciferase
reporter and 0.5 mg of CMV-Renilla luciferase using
FuGENE 6 (Roche Diagnostics). After 24 h, the cells were
pooled and transferred to 24 well plates, then treated
before lysis, and assay for dual luciferase activity according
to the manufacturer’s instructions (Promega). Some
experiments also required cotransfection with an
expression plasmid. For these studies, 1 mg expression
plasmid (SRC1, ERK, or JNK) was included in the reporter
gene transfection mix. Where appropriate, total trans-
fected DNA was maintained by including an empty vector
control, pcDNA5. To control for transfection efficiency,
firefly luciferase counts were normalised with CMV-driven
Renilla luciferase. Dose–response curves were generated
using GraphPad Prism (La Jolla, CA, USA).Quantitative RT (RT-PCR)
Total RNA was prepared from HeLa cells using the RNeasy
Mini Kit with on column DNase I digestion (Qiagen), and
from mouse livers using SV Total RNA Isolation System
(Promega). cDNA was synthesised using a High Capacity
RNA-to-cDNAKit and analysed using Power SYBRGreenPCR
Master Mix (Applied Biosystems). A group of Gc-target genes
were selected from our previous microarray expression
studies (Donn et al. 2007). Quantitative RT-PCR primer
sequences are provided as supplementary information
(SupplementaryTables1 and2, see sectiononsupplementary
data given at the end of this article). Expression levels were
calculated using the comparative Ct method, normalising
with theGAPDHorb-actincontrol, as indicated in the results.Immunoblot analysis
HeLa cells and murine liver tissue (in FastPrep-24 lysing
matrix tubes; MP Biomedicals, Santa Ana, CA, USA) were
lysed using radio-immunoprecipitation assay buffer
(50 mM Tris–HCl, pH 7.4, 1% NP40, 0.25% Na-deoxycho-
late, 150 mM NaCl, and 1 mM EDTA) containing protease
(Calbiochem, San Diego, CA, USA) and phosphatase
inhibitors (Sigma–Aldrich Corp.). The proteins were separ-
ated by SDS gel electrophoresis and transferred to 0.2 mM
nitrocellulose membranes (Bio-Rad Laboratories) overnight
at 4 8C. The membranes were blocked for 6 h (0.15 M NaCl,
1% milk, and 0.1% Tween 20) and incubated with primary
antibodies (diluted in blocking buffer) overnight. Following
three washes (88 mM Tris, pH 7.8, 0.25% dried milk,
and 0.1% Tween 20), membranes were incubated with ahttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0456
 2014 The authors
Printed in Great Britainspecies-specific HRP-conjugated secondary antibody
(in wash buffer) for 1 h at room temperature and washed a
further three times, each for 10 min. Immunoreactive pro-
teins were visualised using ECL Advance (GE Healthcare).Immunofluorescence
Thecellswerefixedwith4%paraformaldehyde for20 minat
room temperature and permeabilised (0.25% Triton X-100
in PBS) for 5 min at room temperature. The cells were
blocked (3% goat serum and 0.1% Triton X-100 in PBS) for
30 min and then in primary antibody (diluted in blocking
buffer) overnight at 4 8C. After three 5 min washes in PBS,
cells were incubated in the secondary antibody for 2 h.
Following three further 5 min washes, coverslips were
mounted using Vectasheild hard-set mounting compound
containing the nuclear DAPI stain (Vector Laboratories,
Burlingame, MA, USA). The images were acquired on a
DeltaVision RT (Applied Precision, Issauah, WA, USA)
restorationmicroscopeusing a!60/1.42PlanApoobjective
and the Sedatfilter set (Chroma89000;ChromaTechnology
Corp., Rockingham, VT, USA). The images were collected
using a CoolSNAP HQ (Photometrics, Tuscon, AZ, USA)
camera with a Z optical spacing of 0.5 mm. The images were
deconvolved using Softworx Software (GE Healthcare,
Issaquah, WA, USA) and maximum intensity projections of
images processed using Image J (http://imagej.nih.gov/ij/;
National Institute of Health, Bethesda, MD, USA).Live cell imaging
Transfection was performed by seeding 1!106 HeLa cells
(Fugene 6) with 5 mg hGR–GFP. After 24 h, the cells were
transferred to glass bottomed 24 well plates. They were
maintained at 37 8C and 5% CO2 for the duration of data
collection. The images were acquired on a Nikon TE2000
PFS microscope using a 60!/1.40 Plan Apo objective and
the Sedat filter set (Chroma 89000) and images collected
using a Cascade II EMCCD camera (Photometrics). Raw
time series images were processed using Image J.Fluorescent recovery after photobleaching
Transfection was performed by seeding 1!106 HeLa cells
(Fugene 6) with 5 mg hGR–GFP overnight then transferred
to glass bottomed 24 well plates. They were maintained at
37 8C and 5% CO2 for the duration of data collection. The
images were collected on a Leica TCS SP5 AOBS inverted
confocal using a 63!/0.50 Plan Fluotar objective and 7!
confocal zoom. The confocal settings were as follows,Published by Bioscientifica Ltd
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format 1024!1024. The images were collected using the
following detection mirror settings; FITC 494–530 nm
using the 488 nm (13%). Raw time series images were
processed using Image J.Proliferation assay
The levels of proliferation were measured using Cell
Titer 96 AQueous One Solution Cell Proliferation Assay
(MTS, Promega) as per instructions provided in the kit.Corticosterone measurements
Corticosterone in serum samples was measured using
enzyme immunoassay (ENZO Life Sciences Ltd, Farming-
dale, NY, USA) as permanufacturer’s instructions. All serum
samples were diluted 1:40 and assayed individually due
to the low volumes obtained. A standard (five-point,
20 000 pg/mlmax)curvecomprisingfivefoldserialdilutions
was generated alongside test samples.Statistical analysis
Data were expressed as averageGS.E.M. (of at least three
independent triplicate experiments) and compared using
SPSS Software (version 16, SPSS, Inc.). For more than two
groups, means were compared by one-way ANOVAA B
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Figure 1
Serum factors induce Gc resistance. HeLa cells were transiently transfected
with MMTV-Luc, Renilla-Luc and GR (A and B) together with pcDNA5 or
SRC1 expression vectors (C and D). Following overnight culture in either
10 or 50% serum, cells were treated with hydrocortisone (HC) (A and C) or
dexamethasone (Dex, 0–100 nM) (B and D) for 16 h before luciferase assay.
Cells were cultured in either 10 or 50% serum, treated with 100 nM Dex for
up to 24 h before immunoblot for GR and PS211-GR (E). Tubulin was used as
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of two groups a Student’s t-test for independent samples or
Mann–Whitney was used. P!0.05 was considered statisti-
cally significant.Results
Serum impairs Gc action through a post-receptor
mechanism
GR is a ligand-activated transcription factor. After nuclear
translocation, ligand-bound GR dimerises and binds
directly to DNA sequences to activate target gene
expression. To study serum regulation of Gc action,
synthetic reporter assays were performed using the GR-
responsive reporter gene MMTV-Luc. Higher serum
concentration (50%) impaired GR transactivation of
MMTV-Luc in response to treatment with either Dex or
hydrocortisone, demonstrable by a markedly decreased
maximum response (reduced efficacy) (Fig. 1A and B).
Overexpression of SRC1, which binds the GR to
potentiate GR transactivation, rescued GR transactiva-
tion, suggesting a reversible model of impaired Gc action
(Fig. 1C and D).
To determine whether the serum effect was
a consequence of modulating GR expression or phos-
phorylation, immunoblot analysis was performed using
global and phospho state-specific antibodies. In responseE F
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a loading control. Cells were transfected with GR–GFP and then cultured in
either 10 or 50% serum overnight. Cells were treated with 100 nM Dex and
imaged in real time. Images were acquired every 5 min. Average time for
GR nuclear translocation in either 10 or 50% serum was calculated and
presented in (F). Representative images are shown (G). Scale bar, 50 mM.
Experiments were performed in triplicate and repeated three times. Graphs
show meanGS.E.M. *P!0.05.
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223 :2 159to Dex treatment, steady state GR expression decreases,
together with an increase in GRS211 phosphorylation,
evident by 1 h (Fig. 1E). Culture in 50% serum did not
affect either the expression or phosphorylation of the GR.
Serum concentration also did not alter cell morphology,
steady-state GR localisation or Dex-induced nuclear
translocation (Supplementary Fig. 1, see section on
supplementary data given at the end of this article). To
investigate the rate of GR subcellular trafficking with
better temporal resolution, live cell imaging was also
completed. Serum had no effect on the rate of Dex-
induced GR nuclear translocation (Fig. 1F and G). FRAP
studies also identified no serum effects on GR intranuclear
mobility either unliganded or after Dex treatment
(Supplementary Fig. 2). Collectively, these studies suggest
that the serum effect is not due to a direct regulation of
GR expression, modification, or subcellular trafficking.Serum selectively and reversibly impairs GR
transactivation of endogenous gene expression
QRT-PCRwas used to explore serum regulation of four well-
characterised GR transactivated genes, metallothionein 1X
(MT1X), FK506 binding protein 5 (FKBP5), Gc-induced
leucine zipper (GILZ, TSC22D3), and period circadian
protein homolog 1 (PER1). Following 4 h Dex treatment,
all four genes were robustly induced: 50% serum impaired
transactivation of both FKBP5 and MT1X (Fig. 2A and B)E
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Figure 2
Serum impairs GR transactivation in a reversible manner. HeLa cells were
cultured in either 10 or 50% serum overnight, then treated with 100 nM
Dex for 4 h before RNA purification. Transcripts of four well-characterised
GR transactivated endogenous genes FK506 binding protein 5 (FKBP5),
metallothionein 1X (MT1X), glucocorticoid-induced leucine zipper (GILZ),
and period circadian protein homolog 1 (PER1) were measured by qRT-PCR
http://joe.endocrinology-journals.org
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Printed in Great Britainwhereas expression of GILZ and PER1 was comparable in
10% and 50% serum (Fig. 2C and D). There were no serum
effects on baseline gene expression or cell proliferation
(Supplementary Fig. 3, see section on supplementary data
given at the end of this article), suggesting that serum
selectively impairs Gc-induced GR activity.
Further qRT-PCR assays were completed to investigate
whether the impairment of GR transactivation was
recovered following return to culture in 10% serum
(Fig. 2E). Impairment of MT1X transactivation was rapidly
reversed (Fig. 2F), whereas FKBP5 regulation was not
recovered even after 8 h (Fig. 2G). This suggests the
existence of different mechanisms regulating variation in
Gc response, acting in a template-dependent manner.
To define further response element specificity of
serum action, two simple Gc response element (GRE)-
reporter genes were examined. Serum had no effect on
either the pTAT3-Luc, which contains tandem repeats of
a simple, consensus GRE (Fig. 3A) or pHH-Luc, which
is a truncated MMTV promoter containing just the GR
binding elements (Fig. 3B). These findings suggest that
target elements may be less important than the flanking,
contextual DNA around the GR binding site for mediating
the serum effect.
As expression of MT1X is transactivated by Zn ions as
well as Gc, the serum effect of Zn transactivation on MT1X
was also determined. The cells cultured in 10% serum had
an eightfold induction of MT1X after treatment with Dex,F G
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Figure 3
Serum increases GR transrepression of IL6 through AP1 elements. HeLa cells
were transiently transfected with TAT3-Luc (A) or pHH-Luc (B), together
with Renilla-Luc and GR. 24 h later, cells were transferred to culture in
either 10 or 50% serum then treated with Dex for 16 h before luciferase
assay. HeLa cells were cultured in either 10 or 50% serum overnight, and
then treated with either 100 nM Dex (C) or 100 mMZnSO4 (D) for 4 h before
RNA purification andMT1X transcript measured by qRT-PCR (normalised to
GAPDH). Cells were cultured in 10 or 50% serum overnight then treated
with 5 ng/ml TNF for 1 h and Dex for a further 4 h. RNA was extracted and
IL6 transcript measured by qRT-PCR (normalised to GAPDH) (E). HeLa cells
were transiently transfected withWTor AP1 deletant IL6-Luc plasmids then
cultured in 10 or 50% serum. Cells were treated with 100 nM PMA and
100 nM Dex for 16 h and then lysed for luciferase assay (F). Graphs show
meanGS.E.M. Experiments were carried out in triplicate and repeated three
times. *P!0.05, **P!0.01, and ***P!0.001. NS, not significant.
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However, both of these robust transcriptional effects were
dramatically decreased following culture with 50% serum,
with only three- and twofold induction of MT1X
respectively (Fig. 3C and D). This further suggests that
the response element contextual DNA is more important
for the serum effect than the GR, or the GR binding site
itself, a conclusion strengthened by observing that GR
repression of IL6 (Fig. 3E), MIF-Luc and IL8 (Supple-
mentary Fig. 4, see section on supplementary data given at
the end of this article) were in fact augmented by culture
in 50% serum. To investigate Gc repression of the IL6 gene
in more depth, additional reporter assays were completed
using a series of human IL6 luciferase constructs.
Consistent with regulation of the endogenous gene, Gc
repression of IL6-Luc was increased in 50% serum.
Interestingly, this augmented Gc repression was lost
when the 5 0AP1-binding site was deleted (Fig. 3F),
implicating AP1 action as part of the mechanism.Serum regulates Gc action through MKK7-activated JNK
To delineate the signalling mechanism responsible for
modulating the Gc response, a series of reporter genehttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0456
 2014 The authors
Printed in Great Britainstudies were performed in conjunction with small
molecule inhibitors. First, Gc-activated expression of
MMTV reporter gene was measured following treatment
with Latrunculin-B, a drug that sequesters G-actin and
inhibits activation of SRF (Gineitis & Treisman 2001,
Gerber et al. 2013). There was no effect on the serum
induction of Gc resistance, suggesting a mechanism
independent of SRF activation (Fig. 4A). To explore the
role of MAP kinases, which activate AP1, in mediating
repression of GR transactivation, cells were treated with
three MAPK inhibitors. Inhibition of JNK reversed the
inhibitory effect serum, whereas inhibition of either ERKs
or p38 had no impact (Fig. 4B). To further specify the role
of JNK, cells were transfected with either JNK or ERK
expression vectors. Hyperactivation of JNK signalling
attenuated GR transactivation and mimicked the serum
effect, such that culture in 50% serum had no additional
effect. Sensitivity to Gc could be restored by co-treatment
with JNK inhibitor (Fig. 4C). Although overexpression of
ERK alone also impaired Gc action, an inhibitory effect of
serum was still observed suggesting coincident activation
of parallel unrelated pathways (Fig. 4D).
To define the role of JNK on endogenous gene
regulation, again cells were transfected with activatedPublished by Bioscientifica Ltd
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Figure 4
Serum impairs Gc action through activation of JNK. HeLa cells were
transiently transfected with MMTV-Luc and GR overnight and then
cultured in 10 or 50% serum. The cells were treated with Latrunculin B
(A) or MAP kinase inhibitors (B) (ERK PD98059, p38 SB203580, and JNK
SP600125) together with 100 nM Dex for 6 h before luciferase assay. The
cells were transiently transfected with MMTV-Luc and GR, together with
JNK (C) or ERK (D) expression vectors (or pcDNA5 as a control) overnight.
The cells were transferred to 10 or 50% serum, treated with 100 nM Dex
and 10 mM JNK inhibitor (SP600125) or ERK inhibitor (PD98059) for 6 h and
then assayed for luciferase activity. HeLa cells were transfected with JNK or
ERK expression vectors (or pcDNA5 as a control), cultured in 10 or 50%
serum, and then treated with 100 nM Dex for 4 h before RNA extraction.
Expression of MT1X (E), FKBP5 (F), GILZ (G), and PER1 (H) transcripts were
measured by qRT-PCR (all normalised to GAPDH). The experiments
were carried out in triplicate and repeated three times. Graphs show
meanGS.E.M. *P!0.05. NS, not significant.
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223 :2 161JNK and then analysed by qRT-PCR. As expected both
MT1X and FKBP5were affected by serum concentration, in
a JNK-dependent manner (Fig. 4E and F) and, induction of
PER1 or GILZ expression by Dex was not affected by serum
or activation of JNK (Fig. 4G and H).Lipid components within serum impair Gc action
We show that culture in 50% serum selectively impairs
GR transactivation through modulation of JNK, and
sought to identify the component in serum responsible
for mediating the effect. Serum contains many growth
factors that signal through tyrosine kinase pathways.
Treatment with genistein, a general inhibitor of tyrosine
kinases, had no effect on serum induction of Gc
resistance (Fig. 5A). In addition neither heat treatment,
nor trypsin digestion of serum impaired the inhibitory
effect of serum on GR action (Supplementary Fig. 5, see
section on supplementary data given at the end of this
article). In search of serum metabolites capable of
regulating Gc function, activated charcoal was used to
‘strip’ small molecules. Culture in 10% charcoal stripped
(delipidated) serum-permitted enhanced GR transacti-
vation at 10%, and had no effect at 50% compared with
full serum (Fig. 5B).http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0456
 2014 The authors
Printed in Great BritainTo further analyse the possible role of serum lipids in
the regulation of Gc action, lipoprotein-deficient serum
(containing !5% of normal lipoprotein) was also used.
Culture in the reduced lipoprotein serum further
increased the Gc response, implicating serum lipids in
negatively regulating Gc responses (Fig. 5C). To pursue
a possible role for cholesterol, cells were loaded with
exogenous cholesterol (25 mmol/l, in a water-soluble
complex with 0.5% methyl-b-cyclodextrin), or with
0.5% methyl-b-cyclodextrin alone (Fig. 5D). Cholesterol
loading decreased GR transactivation, and treatment with
methyl-b-cyclodextrin increased Gc action. Treatment
with Simvastatin, which inhibits cholesterol synthesis,
also potentiated Gc transactivation in either 10 or 50%
serum (Fig. 5E). Importantly, methyl-b-cyclodextrin
increased GR action in a concentration-dependent
manner, where a higher concentration of methyl-b-
cyclodextrin (5%) was necessary to quench the higher
concentration of cholesterol present in 50% serum
(Fig. 5F). The same high concentration of methyl-b-
cyclodextrin was toxic to cells cultured in 10% serum
overnight, presumably a consequence of quenching
available serum cholesterol and also extracting cholesterol
fromcellmembranes and inducing apoptosis. Importantly,
we found onlymodest effects of Simvastatin, cholesterol orPublished by Bioscientifica Ltd
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Figure 5
Modulation of cellular cholesterol regulates Gc effects. HeLa cells were
transiently transfected with MMTV-Luc reporter gene and GR then
transferred to 10 or 50% serum overnight. Cells were treated with
Genistein (as indicated) for 4 h, and then treated with 100 nM Dex for a
further 4 h before lysis and luciferase assay (A). Cells were also cultured in
either normal serum, charcoal stripped serum or lipoprotein-deficient
serum (B and C), and then treated with 100 nM Dex for 16 h before
luciferase assay. Cells were cultured in 10% serumwith 10 mg/ml cholesterol
(CHOL) complexed with 0.5% methyl-b-cyclodextrin (MCD) or with 0.5%
MCD alone (D). Cells transfected with MMTV-Luc and GR, cultured in 10 or
50% serum were treated with Simvastatin (as indicated) together with
100 nM Dex for 16 h before luciferase assay (E). Cells were cultured in 50%
serum, together with cholesterol complexed with 0.5% MCD, 0.5%, or 5%
MCD alone, then treated with 100 nM Dex for 16 h before luciferase assay
(F). Experiments were carried out in triplicate and repeated three times.
Graphs show meanGS.E.M. *P!0.05 and **P!0.01.
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223 :2 162methyl-b-cyclodextrin treatment on cell proliferation or
viability, excluding a possible cell cycle-dependent effect
(Supplementary Fig. 6A, see section on supplementary data
given at the end of this article). We also demonstrate that
treatment with 5%methyl-b-cyclodextrin, which is able to
bind Dex, does not alter the onset of GR translocation
thereby excluding any direct effect of methyl-b-cyclodex-
trin on uptake of Dex by the cells or on the timing of GR
activation (Supplementary Fig. 6B).Cholesterol selectively impairs GR transactivation
through activation of JNK
To investigate the cholesterol effect on GR transactivation
of endogenous genes, the previous group ofhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0456
 2014 The authors
Printed in Great BritainGR-transactivated genes MT1X, FKBP5, GILZ, and PER1
were measured by qRT-PCR. After 4 h treatment with Dex,
incubation with exogenous cholesterol inhibited
induction of MT1X and FKBP5 (Fig. 6A and B), but had no
effect on GILZ or PER1 in cells cultured in 10% serum
(Supplementary Fig. 7A, see section on supplementary data
given at the endof this article). Treatmentwith 5%methyl-
b-cyclodextrin abolished the impact of 50% serum on GR
transactivation of MT1X and FKBP5 (Fig. 6C and D), again
with no effect on GILZ or PER1 (Supplementary Fig. 7B).
There was no cholesterol effect on the baseline expression
of these endogenous genes (Supplementary Fig. 7C). The
liver X receptor (LXR, NR1H3) antagonist GSK1440233A
did not reverse the effect of cholesterol, excluding the
action of oxidised cholesterol through the LXR.
To determine whether the mechanism of cholesterol
action was the same as that seen for culture in high-serum
alone, through activation of JNK, immunoblot analysis
was performed. Indeed, both high serum and cholesterol
loading increased phosphorylation of JNK, a marker of
increased activity. The serum-induced activation of JNK
was attenuated by the addition of 5% methyl-b-cyclodex-
trin (Fig. 6E). The impaired GR transactivation of both
MT1X and FKBP5 after treatment with cholesterol was
rescued by cotreatment with a JNK inhibitor (Fig. 6F and
G), which confirms the requirement of JNK signalling in
mediating the regulatory effect of cholesterol.Cholesterol selectively impairs GR transactivation in vivo
To investigate the effect of high cholesterol on GR
transactivation in vivo, we studied Gc sensitivity in
ApoEK/K mice (Plump et al. 1992). These mice have high
serum cholesterol (Fig. 7A) but have rhythmic corticoster-
one levels within the normal range (Fig. 7B). We
performed a Dex suppression test to measure ‘systemic’
Gc sensitivity and found no difference in response
between WT and ApoEK/K mice (Fig. 7C). Analysis of
protein from the livers of WT and ApoEK/Kmice identifies
no differences in GR expression (Fig. 7D). We next
examined the impact of high serum cholesterol on GR
transactivation in vivo. Consistent with our findings in cell
lines, we find target-specific resistance to Dex treatment in
ApoEK/K mice. Induction of MT1 and Per1 following i.p.
Dex (1 mg/kg, 4 h) was attenuated in ApoEK/K mice, and
although induction of FKBP5 was reduced, this did not
reach statistical significance (Fig. 7E). We found no effect
of cholesterol on Dex-dependent induction of dual
specificity phosphatase 1 (DUSP1), NFkB inhibitor alphaPublished by Bioscientifica Ltd
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Figure 6
Cholesterol regulates GR transactivation via activation of JNK. HeLa cells
were cultured in 10% serum or 10% serum supplemented with 10 mg/ml
cholesterol overnight (A and B), or with 50% serum or 50% serum
supplemented with 5% MCD (C and D). Cells were harvested after 4 h
treatment with either 100 nM Dex or DMSO and analysed by qRT-PCR for
expression ofMT1X and FKBP5 (normalised to GAPDH). HeLa cells cultured
in 10% serum supplemented with 10 mg/ml cholesterol (CHOL) or 50%
serum supplemented with 5% MCD overnight, and then protein lysates
analysed by immunoblot for JNK and phosphorylated JNK (E). Tubulin and
caveolin expression was used as loading controls. Cells were cultured in
10% serum supplemented with 10 mg/ml cholesterol, together with 10 mM
JNK inhibitor (SP600125) for 6 h. Following treatment with 100 nM Dex for
an additional 4 h, expression of GR transactivation of either MT1X (F) or
FKBP5 (G) was measured by qRT-PCR (normalised to GAPDH). Graphs show
averageGS.E.M. Experiments were carried out in triplicate and repeated
three times. *P!0.05 and **P!0.001.
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223 :2 163(NFKBIA) or GILZ (Fig. 7F). High circulating cholesterol
therefore selectively modulates GR function in vivo.Discussion
Optimising Gc treatment is a challenge, a consequence of
wide variation in host sensitivity, localised resistance at
sites of inflammation, and undesired effects attributed to
long-term use. The GR is ubiquitously expressed, and
therefore obtaining selectivity of action is difficult.
Developing selective GR modulators to improve the
therapeutic index of Gc represents an essential step to
improve existing Gc therapies (Beck et al. 2009). However,
as the precise mechanism by which Gcs mediate their
range of anti-inflammatory effects remains unclear,
attempts to identify new molecules with selective action
has proven difficult (Sommer & Ray 2008). Given the
widespread therapeutic application of synthetic Gc in
healthcare, understanding how target cell sensitivity to
Gc is regulated is of major interest. While developing a
Gc bioassay we discovered a potent effect of human serum
on target cell response to Gc (Perogamvros et al. 2011).
Serum is a complex mixture of nutrients and signalling
molecules (hormones, cytokines, and growth factors) and
new discoveries are still being made identifying novel
physiological functions for serum in signalling to targethttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0456
 2014 The authors
Printed in Great Britaintissues, such as providing time-of-day information (Gerber
et al. 2013).
Herein, we show that serum impairs Gc action in a
template-specific manner, where high serum impairs GR
transactivation on some targets, but paradoxically aug-
ments GR transrespression of others. Our studies did not
reveal any differences in GR expression, phosphorylation,
trafficking, or intranuclear mobility either at steady state
or following addition of Gc. These results suggest that the
gene-selective mechanism of action of serum results from
parallel activation of other signalling cascades and
convergence on target genes based on the presence of
transcription factor binding sites for GR, and other factors
lying in such a way as to permit cross-talk. We investigated
several endogenous GR-transactivated genes. Gc-induced
expression of MT1X and FKBP5 was attenuated by serum,
while GILZ and PER1 remains unaffected. Interestingly,
sequence analysis of theMT1X gene sequence showedboth
AP1 and GRE-binding sites in close proximity (Viarengo
et al. 2000, Velazquez &Gariglio 2002). In response to heat
shock, which induces activation of AP1, there was also
reduced Gc transactivation of MT1X (Andrews et al. 1987).
The transcription factor AP1 is dimeric, consisting of
JUN and FOS family members in a variety of homodimeric
and heterodimeric forms. Studies have previously defined
a mutually antagonistic mode of interaction (Lucibello
et al. 1990, Schule et al. 1990), but more recently, AP1 hasPublished by Bioscientifica Ltd
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Figure 7
Cholesterol selectively regulates GR transactivation in vivo. Serum samples
from WT and ApoEK/K mice (eight animals per group) were analysed for
levels of cholesterol, HDL and triglycerides (A). Morning (0700 h) and
evening (1900 h) serum samples from ApoEK/Kmice (16 animals per group)
were assayed for corticosterone (B). WT and ApoEK/K mice were subjected
to a dexamethasone (Dex) suppression test. Mice (eight animals per group)
were given i.p. injection of Dex (1 mg/kg) and then serum collected 4 h
later (1900 h). Serum samples were assayed for corticosterone (C). WT and
ApoEK/K mice (five animals per group) were given i.p. injection of Dex
(1 mg/kg) and then livers collected 4 h later. Livers were analysed for GR
expression by immunoblot (D). Blots show samples from three different
animals. Livers were also analysed for induction of GR target genes MT1,
PER1, and FKBP5 (E), DUSP1, NFKBIA, and GILZ (F) by qRT-PCR (all
normalised to GAPDH). Graphs show meanGS.E.M. *P!0.05 and **P!0.01.
NS, not significant.
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223 :2 164emerged as a necessary pioneer factor for GR access to
target sites in chromatin, suggesting a far more complex
mechanism of interaction than previously thought (Biddie
et al. 2011, Uhlenhaut et al. 2013).
AP1 is activated downstream of MAP kinases, and
using JNK inhibitors and constitutive JNK expression
studies we were able to show that the serum effect required
activation of JNK, and, indeed, serum shock induced JNK
activation. The action of JNK on GR activity and
subcellular shuttling has been previously reported in
other contexts (Rogatsky et al. 1998, Loke et al. 2006).
Having identified a serum effect activating JNK/AP1 as
the mechanism acting on GR signalling, we started by
considering serum components likely capable of activating
JNK. In contrast to other recent studies that identified a
protein factor as themodulatory serum component (Gerber
et al. 2013), we were able to exclude a significant effect
mediated by serum protein components, using heat-
inactivation, trypsin digestion, and growth factor signalling
tyrosine kinase inhibition approaches. Instead, we did
discover a key role for serum lipid components. We show
that the response to Gc was augmented in cells cultured in
charcoal dextran-treated (delipidated) serum, and lipopro-
tein-deficient serum increased Gc action to an even greater
extent. Adding cholesterol alone was sufficient to modify
theGcresponse,which isconsistentwithanearly report that
found high cholesterol blocked the antiproliferative actions
of Gc in leukaemia cells (Madden et al. 1986). We also usedhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0456
 2014 The authors
Printed in Great Britainthe cholesterol-binding drug methyl-b-cyclodextrin to
sequester serum cholesterol (Brown & London 2000,
Simons & Toomre 2000), which not only increased Gc
transactivation in 10% serum culture, but also rescued the
impairment of Gc action by high serum. We found that
loading with exogenous cholesterol alone was sufficient to
activate JNK, and that loss of GR transactivation with
cholesterolwas rescuedbycotreatmentwitha JNKinhibitor.
Treatment with Gc is reported to inhibit cholesterol
synthesis, and so this may provide an indirect mechanism
tomodify JNK signalling, and alsomodify cellular responses
to subsequent Gc treatments (Johnston et al. 1980).
In humans, circulating cholesterol (w100–200 mg/dl
or 2.5–5 mmol/l) is typically higher than that present in
FBS (w30–50 mg/dl or 0.8–1.3 mmol/l) and there are also
differences in lipoprotein content between species. To
assess the role of cholesterol rather than lipoproteins, we
delivered cholesterol directly to target cells in complex
with methyl-b-cyclodextrin and also regulated local
cholesterol production using statin treatment. These
studies reveal a specific effect of cellular cholesterol
content on Gc sensitivity. Given the widespread appli-
cation of cholesterol regulating drugs, and their reported
impact on parameters of inflammation (Krane & Wanner
2011, Rodriguez et al. 2012), this is likely a clinically
relevant interaction.
To explore the effects of high cholesterol on Gc
sensitivity in vivo, we analysed GR function in ApoE null,Published by Bioscientifica Ltd
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223 :2 165hypercholesterolaemic mice. Although globally sensitive
to Gc treatment, we again find target-selective resistance
to Dex in livers from ApoEK/Kmice, although the specific
genes affected were slightly different between human and
murine models. Our in vitro and in vivo data provide strong
evidence for a novel and important regulatory role for
cholesterol in the regulation of Gc responses in vivo.
Gc are key components of the stress response, and are
necessary for regulation of immune and metabolic
function. Our findings therefore have important impli-
cations for patients with dyslipidaemia, treated with
statins, or indeed at foci of inflammation, or injury in
healthy individuals where cholesterol is found at high
concentration.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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